Tim Piotrkowski

And so I do have a feeling that we're going to see something similar.

Yes.

Sorry, I should have been clearer with that.

So this isn't necessarily professional compounding.

This is, yeah.

It very much could be.

And on that, sorry to interrupt, but on that, a lot of these peptides come with claims around 99% purity or other things like this.

Those also aren't tested in a regulated facility or in a public research facility like I had with Roidcheck.

There was no chains of custody or oversight.

And the way that they're being tested, the people involved, there is vested financial interest there.

And so I find it difficult to trust the mechanism.

or the way that that's being done.

And I think other people aren't necessarily savvy to that.

Well, I think APRA is also hamstrung in terms of the evidence available, but...

You're right.

There needs to be a response.

Number one, for those who are prescribing and where there is evidence there, there needs to be sufficient wraparound care for those people.

So, for example, semaglutide or tazepatide, there needs to be sufficient, really, partnership between allied health professionals around that wraparound care in terms of diet and exercise that goes along with these.